Mab

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors

Retrieved on: 
Thursday, January 20, 2022 - 1:30pm

Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for ES002 in September 2021.

Key Points: 
  • Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for ES002 in September 2021.
  • We are very pleased to see ES002 enter clinical trial testing in the United States, said Steve Chin, CMO of Elpiscience.
  • This is an important milestone for Elpiscience as we seek to develop innovative and differentiated cancer immunotherapies.
  • Elpiscience endeavors to advance at least one innovative molecule into the clinic each year to benefit cancer patients worldwide.

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors

Retrieved on: 
Thursday, January 20, 2022 - 1:30pm

Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for ES002 in September 2021.

Key Points: 
  • Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for ES002 in September 2021.
  • We are very pleased to see ES002 enter clinical trial testing in the United States, said Steve Chin, CMO of Elpiscience.
  • Elpiscience is a clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy to benefit cancer patients worldwide.
  • It has four molecules in clinical trials (ES002, ES101, ES102, and ES104), and endeavors to clinically advance at least one innovative molecule a year.

OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

Retrieved on: 
Monday, January 17, 2022 - 6:30am

NANTES, France, Jan. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer.

Key Points: 
  • NANTES, France, Jan. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer.
  • Dominique Costantini, current Chairwoman of OSE Immunotherapeutics Board of Directors, and previously CEO from 2012 to 2018, has been appointed interim Chief Executive Officer, effective immediately.
  • Alexis Peyroles is stepping down for health reasons and he remains committed to OSEs success.
  • Dominique Costantini, Chairwoman and Chief Executive Officer of OSE Immunotherapeutics, said: We thank Alexis for his strong involvement and wish him the very best.

Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology

Retrieved on: 
Friday, January 14, 2022 - 1:51pm

The grant of this patent provides further recognition of the high quality of the innovation being carried out by Oblique Therapeutics' team.

Key Points: 
  • The grant of this patent provides further recognition of the high quality of the innovation being carried out by Oblique Therapeutics' team.
  • Owe Orwar, Ph.D., Professor, Founder and CEO of Oblique Therapeutics says:
    "We are absolutely thrilled by the news from USPTO.
  • We are today developing a number of programs out of the AbiProt platform with a focus on pain and aggressive cancer.
  • Oblique Therapeutics is applying this technology for discovery of a new generation of selective antibody therapeutics targeting cancer and pain.

Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology

Retrieved on: 
Friday, January 14, 2022 - 1:48pm

The grant of this patent provides further recognition of the high quality of the innovation being carried out by Oblique Therapeutics' team.

Key Points: 
  • The grant of this patent provides further recognition of the high quality of the innovation being carried out by Oblique Therapeutics' team.
  • Owe Orwar, Ph.D., Professor, Founder and CEO of Oblique Therapeutics says:
    "We are absolutely thrilled by the news from USPTO.
  • We are today developing a number of programs out of the AbiProt platform with a focus on pain and aggressive cancer.
  • Oblique Therapeutics is applying this technology for discovery of a new generation of selective antibody therapeutics targeting cancer and pain.

Zoetis Announces FDA Approval of Solensia™ (frunevetmab injection) to Control Osteoarthritis Pain in Cats

Retrieved on: 
Thursday, January 13, 2022 - 6:36pm

The approval of Solensia is a significant step forward in the control of feline OA pain.

Key Points: 
  • The approval of Solensia is a significant step forward in the control of feline OA pain.
  • Solensia works differently than other available treatments by targeting Nerve Growth Factor (NGF), a key driver of OA pain.
  • NGF activates and perpetuates the pain signal by increasing the release of additional pain and inflammation mediators.4 By targeting NGF, Solensia reduces pain signals and effectively controls feline OA pain.
  • Solensia is a monoclonal antibody therapy administered in the clinic that targets Nerve Growth Factor (NGF) to control feline OA pain.

FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

Retrieved on: 
Thursday, January 13, 2022 - 3:10pm

Advancements in modern veterinary medicine have been instrumental in extending the lives of many animals, including cats.

Key Points: 
  • Advancements in modern veterinary medicine have been instrumental in extending the lives of many animals, including cats.
  • The two clinical trials were both masked, randomized, controlled field studies involving client-owned cats with clinical signs of osteoarthritis.
  • The cats' veterinarians assessed the cats based on orthopedic examinations before and after treatment.
  • Overall, the cats in the treatment group had better assessment scores than those in the control group.

Tiziana Life Sciences Announces Death of Director

Retrieved on: 
Thursday, January 13, 2022 - 12:00pm

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (Tiziana), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that Dr. Thomas Adams passed away on January 9, 2022.

Key Points: 
  • NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (Tiziana), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that Dr. Thomas Adams passed away on January 9, 2022.
  • He served as a member of Tiziana Life Sciences Board of Directors since February 2021.
  • Although he joined the Board a year ago, Dr. Adams had been involved with Tiziana over a number of years.
  • Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.

Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

Retrieved on: 
Wednesday, January 12, 2022 - 9:56pm

WALTHAM, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today summarized recent findings reported in three separate publications that show ADG20, its lead monoclonal antibody (mAb), has neutralization activity against the Omicron (B.1.1.529) variant of SARS-CoV-2, and outlined initiatives to address current and future SARS-CoV-2 variants of concern. Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. Adagio is engaging with the U.S. Food and Drug Administration (FDA) regarding potential protocol updates to its global Phase 2/3 clinical trials, including an increased dose of ADG20 for the potential prevention and treatment of COVID-19 resulting from the Omicron variant.

Key Points: 
  • Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19.
  • Findings across all three studies show that among mAbs in late-stage clinical development or with Emergency Use Authorization (EUA), ADG20 is one of only a few mAbs that demonstrated neutralizing activity against Omicron.
  • In addition to its clinical trial updates, Adagio is pursuing multiple strategies to address both Omicron and potential future variants that may emerge.
  • In vitro data from a variety of preclinical studies have shown that ADG20 retains neutralizing activity against all known SARS-CoV-2 variants of concern.

Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 12, 2022 - 1:30pm

SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) --  Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will discuss the following updates at the 40th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will discuss the following updates at the 40th Annual J.P. Morgan Healthcare Conference.
  • The US FDA has granted Fast Track Designation for Prometheus lead therapeutic candidate, PRA023, for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).
  • If successful in Phase 2 clinical trials, Prometheus would seek Breakthrough Therapy Designation in SSc-ILD given that there are currently no approved disease modifying therapies."
  • Presentation at the 40th Annual J.P. Morgan Healthcare Conference
    Prometheus will webcast its corporate presentation from the 40th Annual J.P. Morgan Healthcare Conference today, January 12, 2022 at 1:30 PM ET.